Medical technology company Know Labs revealed that its Bio-RFID sensor was able to quantify different analytes in vitro in a proof-of-principle study.

The study has been carried out in collaboration with Mayo Clinic.

The Bio-RFID technology platform developed by Know Labs sends electromagnetic energy in the form of radio waves through the skin to capture molecular signatures in a non-invasive manner.

These signatures can then be transformed into physiologically relevant information and insights.

The technology has demonstrated its capability to accurately measure various analytes both within and outside the body, though the company is planning to initially use the technology for non-invasive glucose monitoring.

Know Labs CEO and chairman Ron Erickson said: “Proof-of-principle studies are critical in demonstrating Bio-RFID’s accuracy for non-invasive methods of medical diagnostics.

“This was an essential step toward achieving our goal of delivering the first FDA-cleared, truly non-invasive glucose monitoring device to the market.”

Named ‘Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions – Implications for Non-Invasive Physiologic Monitoring’, the study was conducted at Mayo Clinic in Rochester, Minnesota.

The study proved the Bio-RFID sensor’s capacity to non-invasively measure concentrations of solutions in a randomised double-blind trial through five experiments.

These experiments were designed to use proxies for biochemical solutions which included water in isopropyl alcohol, commercial bleach in water and sodium chloride in water.

The Bio-RFID sensor was utilised to gather data during the tests. It generated radio frequency signals and measured the received power via an antenna array.

All of the solutions in the test data were correctly identified for each experiment. The Bio-RFID technology could identify concentrations as low as 2,000 parts per million.

As well as this proof-of-principle study, Know Labs is conducting a series of studies as part of its plans for external validation of its Bio-RFID technology for non-invasive, highly accurate detection and measurement of glucose and other analytes in the body.